Skip to content

Efficacy of low-dose scopolamine combined with palonosetron based on opioid-free anesthesia for preventing postoperative nausea and vomiting in high-risk patients undergoing total knee arthroplasty: a prospective randomized double-blind controlled trial

Efficacy of low-dose scopolamine combined with palonosetron based on opioid-free anesthesia for preventing postoperative nausea and vomiting in high-risk patients undergoing total knee arthroplasty: a prospective randomized double-blind controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600129031
Enrollment
Unknown
Registered
2026-07-29
Start date
2026-08-04
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative nausea and vomiting after total knee arthroplasty

Interventions

Opioid-free anesthesia plus dual antiemetic group:Opioid-free general anesthesia combined with dual antiemetics for PONV prophylaxis
Opioid-containing anesthesia routine antiemetic control group:Conventional opioid-containing anesthesia combined with standard clinical dual antiemetic regimen
Opioid-containing anesthesia plus dual antiemetic group:Conventional opioid-containing anesthesia combined with dual antiemetics for PONV prophylaxis

Sponsors

Zigong Fourth People's Hospital(Zigong First-aid Center)
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Aged over 60 years old; 2.ASA physical status ?–?; 3.BMI 18–30 kg/m^2; 4.Having at least three PONV risk factors (female gender, history of motion sickness or PONV, non-smoker, planned postoperative opioid analgesia); 5.Scheduled for elective total knee arthroplasty (TKA).

Exclusion criteria

Exclusion criteria: 1.Sick sinus syndrome, second-degree or higher atrioventricular block, or resting heart rate less than 50 beats per minute; 2.Moderate to severe cardiac, pulmonary, hepatic or renal insufficiency; 3.Parkinson’s disease, Alzheimer’s disease, epilepsy; 4.Pregnancy or lactation; 5.Coagulation disorders; 6.Uncontrolled diabetes mellitus; 7.Glaucoma; 8.Known hypersensitivity to investigational drugs of this study.

Design outcomes

Primary

MeasureTime frame
Incidence of postoperative nausea and vomiting within 24 hours after surgery;

Secondary

MeasureTime frame
Postoperative rehabilitation related indicators;Incidence of perioperative drug-related adverse events;Severity of PONV at different postoperative periods and usage rate of rescue antiemetics;

Countries

China

Contacts

Public ContactYu Gu

Zigong Fourth People's Hospital(Zigong First-aid Center)

guyu951221@163.com+86 18990031204

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026